Syngeneic Tumor Cells
Syngeneic Tumor Cells - Related Videos
08:01
Quantifying the Frequency of Tumor-propagating Cells Using Limiting Dilution Cell Transplantation in Syngeneic Zebrafish
0 Views •
Cited by 35 •
2011
Limiting dilution cell transplantation assays are used to determine the frequency of tumor-propagating cells. This protocol describes a method for generating syngeneic zebrafish that develop fluorescently-labeled leukemia and details how to isolate and transplant these leukemia cells at limiting dilution into the peritoneal cavity of adult zebrafish.
05:06
A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
0 Views •
Cited by 2 •
2015
The metastatic spread of cancer is the major cause of cancer-related deaths. We provide an in-depth description of our survival surgery methodology for establishing a “patient-like” orthotopic syngeneic mouse model system for studying the mechanisms of metastasis in solid organ tumors.
02:42
An In Vitro Assay to Evaluate the Anti-Tumor Activity of Tumor-Specific CAR T Cells
0 Views •
2025
This video demonstrates an in vitro assay to validate chimeric antigen receptor (CAR) T cell activity. B-cell lymphoma cells expressing CD19 antigen and cytoplasmic luciferase are co-cultured with CD19-specific CAR T cells. CAR binding to CD19 on a tumor induces the CAR T cells to release cytokines and toxins that cause tumor cell cytotoxicity. The CAR T cell activity is evaluated by quantifying the released cytokine and decreased luciferase-mediated bioluminescence in the tumor cells.
07:31
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
0 Views •
Cited by 13 •
2016
Metastasis plays a profound role in the virulence of cancer, accounting for an estimated 90% of deaths. We report a protocol for a metastatic melanoma model in mice that is useful for determining the efficacy of therapeutic agents against this clinical phenomenon.
05:22
Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
0 Views •
Cited by 8 •
2015
Circulating tumor cells (CTCs) have been shown to play an important role in tumor metastasis. Here, a method for the isolation and propagation of CTCs from the whole blood of a syngeneic mouse tumor model of hepatocellular carcinoma (HCC) metastasis is described.
FAQs
Genetic matching prevents allogeneic rejection, allowing implanted cancer cells to persist in the host animal. This creates an immunocompetent setting in which tumor-associated signals remain available for interaction with the host immune system. Researchers can therefore study tumor behavior alongside immune surveillance and other host responses, rather than examining cancer growth in isolation from immune activity.
A genetically mismatched implant can trigger allogeneic rejection, complicating interpretation of tumor growth and immune responses. Syngeneic tumor cells avoid that incompatibility when placed in genetically matched mice. The resulting model preserves interactions between the cancer and an intact immune system, making it particularly useful for studying immune-mediated effects on tumor development.
T cells, macrophages, and other stromal components participate in the tumor environment surrounding the implanted cells. Their presence allows investigators to examine how cancer cells interact with immune and supporting tissues during tumor growth. This broader cellular context helps connect tumor-associated signals with immune surveillance and the behavior of the tumor microenvironment.
Researchers first use tumor cells compatible with the genetic background of the selected mice, then implant the cells into those animals. Subsequent assessments can address tumor growth, metastasis, immune surveillance, or changes in the tumor microenvironment. The workflow preserves an intact immune setting, allowing treatment responses and tumor-host interactions to be examined together.
These models are especially useful when investigators need to assess immunotherapies, combination treatments, or mechanisms of therapeutic resistance in the presence of an intact immune system. Because the tumor can interact with immune and stromal components, treatment studies can examine not only tumor behavior but also how immune surveillance contributes to therapeutic outcomes.
Studies using these cells can address tumor growth, metastatic behavior, immune surveillance, and the tumor microenvironment. They also support analysis of how treatments perform against cancer while immune and stromal interactions remain active. In preclinical medicine, those findings can help identify promising strategies and resistance mechanisms before progression to more complex studies.